Masthead

Tackling T-cell Lymphoma

| Comments (0)

Of the approximately 76,000 new patients who will be diagnosed with non-Hodgkin lymphoma (NHL) this year, 15% will have peripheral T-cell lymphoma (PTCL).

The World Health Organization (WHO) lists 21 major subtypes of mature PTCL. Therefore, because of the relatively rare heterogeneity of the disease, PTCL is more challenging than other types of NHL from diagnostic and therapeutic points of view.

To meet these challenges, we've assembled a world-class team of medical oncologists, dermatologists, radiation therapists, hematopathologists and stem cell transplant experts to create a multidisciplinary T-cell lymphoma working group. During the monthly meeting of our group, which I chair, we discuss challenging cases and recent clinical and pre-clinical data in PTCL, in addition to new concepts to design and conduct innovative clinical trials for PTCL patients.

Our mission is to improve the cure rate of patients with PTCL and reduce treatment-related toxicity by developing novel targeted therapy using rationally designed small molecules, antibodies and combination regimens of biologic agents.




Our current trials include histone deacetylase inhibitors, antibody-drug conjugates and a variety of small molecule inhibitors that target activated oncogenic pathways to promote tumor cell survival. Our work is funded in part by a lymphoma SPORE (Specialized Programs of Research Excellence) grant.

For referrals, please contact me at ayounes@mdanderson.org or Amanda Copeland at ARCopeland@mdanderson.org.

Resources

The T-Cell Lymphoma working group includes:
Anas Younes, M.D. (T-cell lymphoma team leader)
Yasuhiro Oki, M.D.
Michelle Fanale, M.D.
Madeleine Duvic, M.D.
Bouthaina Dabaja-Shbib, M.D.
Jeffrey Jorgensen, M.D.
Francisco Vega-Vasquez , M.D.
Issa Kurie, M.D.
Chitra Hosing, M.D.
Amanda Copeland, APN

Leave a comment

Search

Connect on social media

Sign In

Archives